5th July 2022 | Pharma Updates

PharmaState Updates – Latest Pharma Happenings

Union Health Minister discusses Indian Pharma sector roadmap

The pharmaceutical industry should accelerate its growth trajectory in the future years, Union Health Minister Mandaviya stated, in line with the Prime Minister’s goal of achieving Aatmanirbharta in all disciplines.

41 doctors warned for doing advertisements in Uttarakhand

For agreeing to appear in advertising on hoardings, banners, and newspapers, the Uttarakhand Medical Council has issued notices to 41 doctors in the past six months for violating its “Professional Conduct, Etiquette and and Ethics Regulations, 2002. “

Medical professionals miffed by imposition of 10% TDS on free medical samples

According to new recommendations released by the Central Board of Direct Taxes, doctors among others would be obliged to pay 10% TDS on gifts given to them such free samples if the value of the gifts is over Rs. 20,000 as of July 1, 2022.

Diabetes and blood pressure medications to be cheaper by the end of the month

The price of 84 formulations has been reduced by the National Pharmaceutical Pricing Authority. By the end of July, nevertheless, this might have an effect on city markets.

National drug regulators' conference wants MDTL in all states

An exclusive testing laboratory for medical devices is urgently needed in the capital of Telangana, as per the findings of the first national conclave of the central and state drug regulatory officers held in Hyderabad under the banner of the “DCO India Forum. “

Sanofi introduces a global health brand focused on non-profit treatments

In the first phase of its strategy to improve access to its medications globally, the French pharmaceutical company Sanofi will make 30 of its therapies, including insulin, freely available in 40 lower-income nations.

Aurigene announces partnership with EQRx & commitment to drug advancement

The collaboration combines Aurigene’s small molecule drug discovery platform with EQRx’s novel business model to speed the development of drug candidates in oncology and immune-inflammatory illnesses and promote global access to new medications.